ClinVar Miner

Submissions for variant NM_005591.3(MRE11):c.1032T>G (p.Leu344=) (rs11020793)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000129049 SCV000183744 benign Hereditary cancer-predisposing syndrome 2014-12-17 criteria provided, single submitter clinical testing Seen in trans with a mutation or in homozygous state in individual without severe disease for that gene
GeneDx RCV000212565 SCV000211160 benign not specified 2014-01-09 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Invitae RCV001081395 SCV000261668 benign Ataxia-telangiectasia-like disorder 2020-12-06 criteria provided, single submitter clinical testing
Counsyl RCV000410736 SCV000488849 benign Ataxia-telangiectasia-like disorder 1 2016-07-12 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000586471 SCV000698600 benign not provided 2017-07-06 criteria provided, single submitter clinical testing Variant summary: The MRE11A c.1032T>G (p.Leu344Leu) variant involves the alteration of a conserved nucleotide, resulting in a synonymous change located in the Mre11, DNA-binding (IPR007281) (InterPro). One in silico tool predicts a damaging outcome for this variant. 5/5 splice prediction tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant of interest has been found in a large, broad control population, ExAC in 321/121170 control chromosomes (9 homozygotes) at a frequency of 0.0026492, which is approximately 42 times the estimated maximal expected allele frequency of a pathogenic MRE11A variant (0.0000625), suggesting this variant is likely a benign polymorphism. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as benign. The variant of interest has not, to our knowledge, been reported in affected individuals via publications and/or reputable databases/clinical diagnostic laboratories; nor evaluated for functional impact by in vivo/vitro studies. Taken together, this variant is classified as benign.
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000410736 SCV001471736 benign Ataxia-telangiectasia-like disorder 1 2019-11-20 criteria provided, single submitter clinical testing
Athena Diagnostics Inc RCV000212565 SCV001476692 benign not specified 2020-02-20 criteria provided, single submitter clinical testing
Genome Diagnostics Laboratory, Amsterdam University Medical Center RCV000212565 SCV001806975 benign not specified no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.